Amgen Issues Statement in Response to Revised ESA Labeling Received from the FDA Today

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen (NASDAQ: AMGN) issued the following statement in response to the receipt today of the complete response on the revised ESA labeling from the FDA.